Key Takeaway: Enanta Pharmaceuticals has reported positive topline results from its Phase 2 SPRINT trial evaluating EDP-235 in standard risk COVID-19 patients. Additionally, the company announced favorable data from a Phase 1 clinical study of EDP-323, an oral L-Protein inhibitor for respiratory syncytial virus. Furthermore, EDP-323 has received FDA Fast Track Designation, enhancing its development prospects.
Price reaction · baseline $10.08 (2024-01-02 close) · hit pre-market · clean, no other ENTA news in the window
day 0 close · peak
+5%
Market Sentiment Analysis
POSITIVE FACTORS
Positive topline results from the Phase 2 SPRINT trial for EDP-235.
Successful Phase 1 study results for EDP-323 targeting RSV.
FDA Fast Track Designation received for EDP-323.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19
Full Press Release Details
Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
Frequently Asked Questions
What were the results of the Phase 2 SPRINT trial?
The Phase 2 SPRINT trial for EDP-235 reported positive topline results.
What is EDP-323 used for?
EDP-323 is an oral L-Protein inhibitor in development for treating respiratory syncytial virus.
What designation did EDP-323 receive from the FDA?
EDP-323 received FDA Fast Track Designation.
What is the significance of the Phase 1 study results?
The Phase 1 study of EDP-323 showed favorable data, supporting its development.